BCL2 and fibrosarcoma: We investigated whether such effects would also apply to orthotopic tumors, in particular MCA205 cutaneous fibrosarcomas and TC1 non-small cell lung cancers (NSCLC), which are not particular susceptible to in vitro killing by BCL2 inhibitors unless very high concentrations (≥10 μM) are used (Fig. S4A,B).